Efficacy and Safety of Nitazoxanide 600 Mg in the Outpatient Treatment of COVID-19 and Influenza

Launched by AZIDUS BRASIL · Feb 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness and safety of a medication called nitazoxanide for treating COVID-19 and influenza in outpatient settings. Participants in the trial will take a dose of 600 mg of nitazoxanide, or a placebo (a dummy pill), twice a day for seven days. They will also keep a diary to track their symptoms and any other medications they are taking. After a week, they will visit the clinic for a check-up to assess their health and safety.

To participate, individuals must be at least 18 years old and have been diagnosed with COVID-19 or influenza within the last 48 hours. They cannot have certain health conditions, such as severe heart, liver, or kidney problems, or be pregnant or breastfeeding. This trial is not yet recruiting participants, but it aims to help understand if nitazoxanide can be a beneficial treatment for these viral infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signed informed consent form;
• • Male or female;
• • Age ≥ 18 years;
• • COVID-19 or influenza diagnosed by rapid test, with symptom onset less than 48 hours ago;
• • Clinical condition compatible with outpatient treatment.
• Exclusion Criteria:
• • Known hypersensitivity to nitazoxanide;
• • History of cardiomyopathies, hepatopathies, or nephropathies;
• • Antineoplastic treatment with chemotherapy or radiotherapy;
• • Severe autoimmune diseases with immunosuppression;
• • Transplant recipients;
• • Any uncompensated systemic disease at the investigator's discretion;
• • Participation in clinical studies in the last 12 months;
• • Pregnant or breastfeeding individuals;
• • Suspected bacterial coinfection or prescription of antibiotic therapy at enrollment;
• • Diagnosis of neurological disease (traumatic brain injury, stroke, Parkinson's disease, Alzheimer's disease, other dementias);
• • Diagnosis of developmental disorder (ADHD, ASD, learning disabilities, intellectual disability, Rett syndrome);
• • Significant hearing or vision impairment.